A Phase 2 interventional study of [68Ga]Ga-FAPI-46 in Malignant Melanoma Stage IV, sponsored by Barbara Malene Fischer. Recruiting at 2 sites in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-10-10.
Sponsored by Barbara Malene Fischer · Phase 2, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 86 studies in Melanoma with a site in Denmark — 16 open to participants now, 28 under way, 7 of them phase 3. Melanoma · Denmark.
Among the 86 studies in Melanoma with a site in Denmark, this one is the 55th largest by planned enrollment of the 73 interventional ones that give a count, is one of 4 that started in 2025, is one of 12 in phase 2, reaches primary completion later than 13 of the 27 other live ones, and was the 84th registered.
3,374 studies on the registry are indexed under Melanoma; 579 are open to participants now.
Browse Melanoma studies →16 of the 86 studies in Melanoma with a site in Denmark are open now. Recruiting first, the newest first:
Inge Marie Svane · Sites in Denmark
Ages 18+
IDEAYA Biosciences · Sites in Denmark, United States, Australia and 18 more countries
Ages 18+
Inge Marie Svane · Sites in Denmark
Ages 18–75
Inge Marie Svane · Sites in Denmark
Ages 18–75
Immunocore Ltd · Sites in Denmark, United States, Argentina and 23 more countries
Ages 18+
A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →
Of the 467 Melanoma studies recruiting now, 379 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
86 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 26 · Phase 2 25 · Phase 3 22 · Phase 4 1
First in 1998; this study’s year is marked. 4 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 20 is below the median of 40 across 2,652 interventional studies indexed under Melanoma.
Median enrollment 134 across the 73 interventional studies, 100 across the 11 observational. Of the 53 that completed or were terminated, 22 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
40 of 86 have an industry lead sponsor. The 10 most frequent:
Barbara Malene Fischer is the lead sponsor of 2 studies on the registry; 2 are open to participants now.
Barbara Malene Fischer has 1 study filed under Melanoma — fewer than ten, so there is no comparison to draw.
7 of the studies in Melanoma with a site in Denmark that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06112314Phase 3Immunocore LtdIMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301) | 2027-10-16 |
| NCT06961786TILT Biotherapeutics Ltd.TNFα and IL-2 Coding Oncolytic Adenovirus TILT-123 With Lymphocyte-depleting Chemotherapy and TILs in the Treatment of Melanoma | 2026-11 |
| NCT06783270Inge Marie SvaneT-cell Therapy with CRISPR PD1-edited Tumor Infiltrating Lymphocytes for Patients with Metastatic Melanoma | 2027-01-01 |
| NCT04855435MonTa Biosciences ApSSafety and Preliminary Efficacy of MBS8(1V270) in Cancer Patients With Advanced Solid Tumours | 2027-03 |
| NCT06204991Inge Marie SvaneTo Evaluate the Safety and Efficacy of ADP-TILIL7 in Patients With Locally Advanced or Metastatic Melanoma | 2027-03-01 |
Add all 7 to your calendar (.ics) → With an account.
Among the 86 studies in Melanoma with a site in Denmark, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to investigate the use of the tracer [68Ga]Ga-FAPI-46 for PET/CT-imaging in response evaluation of patients with advanced stage malignant melanoma treated with immune checkpoint inhibitor therapy (ICT). The main question it aims to answer is:
Researchers will compare findings on the experimental [68Ga]Ga-FAPI-46 PET/CT with findings on standard imaging ([18F]FDG PET/CT).
Participants will undergo:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with advanced stage malignant melanoma with visible lesions on \[18F\]FDG PET/CT referred for ICT at the Dept. of Oncology Herlev Hospital will be sought enrolled. Patients will undergo two \[68Ga\]Ga-FAPI-46 PET/CT, which include injection with the experimental tracer \[68Ga\]Ga-FAPI-46. These scans are in addition to their standard imaging.
Drug: [68Ga]Ga-FAPI-46
Patients undergo two PET/CTs with the experimental tracer \[68Ga\]Ga-FAPI-46 (drug).
Changes in FAPI-uptake in malignant lesions on [68Ga]Ga-FAPI-46 PET/CT during ICT
Specified malignant lesions will be defined and evaluated by a team of specialists on the baseline \[68Ga\]Ga- FAPI PET/CT scan and the uptake of the FAPI tracer in the lesions will be quantified. The evaluation of the malignant lesions on \[68Ga\]Ga-FAPI PET/CT will also be compared with a similar lesion evaluation on the \[18F\]FDG PET/CT (standard imaging). The FAPI-uptake will be reassessed after 12 weeks of ICT by the same team of specialists. Changes in uptake of malignant lesions after 12 weeks of ICT on the \[68Ga\]Ga-FAPI-46 PET/CT will be compared to changes on the \[18F\]FDG PET/CT and the clinical response. The clinical response will be assessed using the patients' medical record.
Time frame: From enrollment in the study (signed informed consent) to after the second [68Ga]Ga- FAPI PET/CT, estimated time is 3 months.
Changes in [68Ga]Ga-FAPI-46-uptake during ICT in healthy tissue
Tracer-uptake in healthy tissue and benign lesions on \[68Ga\]Ga-FAPI-46 PET/CT will be evaluated using the same method as described in "Primary Objectives". A similar evaluation of standard \[18F\]FDG PET/CT will be performed. FAPI-uptake in healthy tissue on \[68Ga\]Ga-FAPI-46 PET/CT will be compared to the findings on \[18F\]FDG PET/CT. To verify the \[68Ga\]Ga-FAPI-46 PET/CT assessment (including evaluation of healthy tissue, malignant lesions and benign lesions), the assessment will be compared to the findings from a composed reference standard. This consist of all available imaging, biopsy results, blood tests, and information on hospitalization and changes in patient management up to 6 months after the \[68Ga\]Ga-FAPI PET/CT.
Time frame: From enrollment in the study (signed informed consent) to the end of the follow-up (6 months after the second [68Ga]Ga-FAPI-46 PET/CT, estimated time in total is 9 months from signed informed consent).
Correlation between [68Ga]Ga-FAPI-46-uptake on [68Ga]Ga-FAPI-46 PET/CT and levels of FAP-activity biomarkers in serum blood samples during ICT.
Blood samples from the included participants will be analyzed by Nordic Bioscience- Results from this analysis will be correlated to the disease activity evaluated on the \[68Ga\]Ga-FAPI-46 PET/CT. Results from the serum blood sample analysis will also be correlated with treatment outcome after 6 months of treatment. Treatment outcome will be defined using the RECIST criteria (40). This analysis will be done retrospectively on routine clinical scans (\[18F\]FDGPET/CT). The updated guideline and definitions of the RECIST criteria will be used.
Time frame: From enrollment in the study (signed informed consent) to the end of the follow-up (6 months after the second [68Ga]Ga-FAPI-46 PET/CT, estimated time in total is 9 months from signed informed consent).
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided
Started Aug 2025 (actual). Primary completion is estimated for Aug 2026, 12 months after the start.
Of 277 non-industry phase 2 interventional studies under Melanoma, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 94. This study's planned 12 months is below that.
Counting every sponsor, half of 383 studies reached it within 53 months; a quarter within 32 and three quarters within 88.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: FAPI-46 GA-68
Barbara Malene Fischer